MedTrace Logo

Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19 (COVITOZ-01)

NCT04435717 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2021-08-30

No results posted yet for this study

Summary

unicenter, randomized, open-label clinical trial on the efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19.

Conditions

  • Covid19

Interventions

DRUG

Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1

Tocilizumab 20 MG/ML Intravenous (one dose)

DRUG

Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (2 doses)

Tocilizumab 20 MG/ML Intravenous ( two doses)

Sponsors & Collaborators

  • Hospital Universitario Ramon y Cajal

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-04
Primary Completion
2020-11-04
Completion
2021-02-10

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04435717 on ClinicalTrials.gov